May 2025 | Issue:05

Veeda™ Lifesciences

THE VEEDA NEWSLETTER

Turning Global Data into Trial Decisions

At Veeda, we integrate real-world data, advanced analytics, and deep regional expertise to drive smarter site strategies and impactful clinical results-worldwide.

Inside Veeda Group: May 2025

info@veedalifesciences.com
www.veedalifesciences.com

Excellence In Everything

From the CEO's DESK

Veeda™ Lifesciences

Where Data Drives Action: Veeda's Data Solutions Empowering Global Research Solutions

At EMN 2025 in Athens, I had the opportunity to engage with leading investigators in the field of multiple myeloma who echoed a message that deeply resonated: "It's not only about where trials are conducted —it's about how the patients in the trial are served." In clinical research, it is about firstly understanding and then serving patient needs. It's about providing a high level of attention to detail, strong scientific expertise and operational execution, all of which reinforce our belief that successful trials begin with informed, data driven decision making providing actual patient solutions.

At Veeda Lifesciences, we've built a global trial ecosystem that serves as the foundation for delivering high-quality research. What excites me now is how we are enhancing this framework with AI-backed data solutions. We are drawing from real-time global trial data to refine how we identify sites, engage investigators, plan feasibility, and align patient recruitment with biomarker insights. Our focus is to ensure every trial decision is more informed, more relevant, and closely aligned with both scientific rigor and patient need.

We look forward to continuing these conversations at EHA (European Hematology Association), ASCO, and BIO US, where Veeda teams will interact with the scientific community for detailed discussions. Each conference gives us a unique opportunity-EHA for scientific depth in haem-onc, ASCO for broader oncology insights, and BIO US to engage with innovators across biologics, biosimilar developers, and vaccine manufacturers. Through it all, we remain committed to advancing research with clarity, collaboration, and purpose.

Warm Regards,
Dr. Mahesh Bhalgat
Group CEO & MD, Veeda Lifesciences

Veeda Voice

Veeda at Swiss Biotech Day 2025

André Bongartz, Director of Business Development at Veeda, represented the company at Basel, joining global leaders for impactful biotech conversations and future-focused collaborations.

Celebrating Clinical Trials Day with Heartfelt Reflections

Veeda Lifesciences team marked Clinical Trials Day by sharing personal reflections and honoring the collective efforts behind every trial.



Heading to BIO 2025 in Boston

We're eager to understand your pipeline and therapeutic focus—where you are in development and what support you need.Through our integrated preclinical, clinical, and biopharma units, we tailor solutions that minimise bottlenecks and drive your drug's journey to market with agility and confidence.

Explore Opportunities on Veeda's New Careers Page

We've launched a newly designed Careers page to help future talent discover roles, understand our culture, and grow with us. Explore, apply, and become part of Veeda's journey.

Industry INSIDER

Veeda Lifesciences™

Indian healthcare's tech adoption pivots around AI powered clinical systems, blockchain, VR & Big Data

Indian healthcare sector is poised for a significant transformation, driven by the integration of advanced technologies. Artificial intelligence (AI) is becoming a core component of clinical workflows...

Read More

Indian pharma works to prioritize employee centricity with tech-driven HR practices

Indian pharma continues its global ascent, building resilient, tech-savvy, and people-first HR ecosystems. Flexibility and continuous learning are not just buzzwords but are foundation of a future-ready workforce...

Read More

CDSCO declares 196 drug samples tested in April as NSQs

The drug regulators in the country have reported a significant jump in the number of Not of Standard Quality (NSQ) drug samples in the routine regulatory surveillance activity during the month of April, 2025...

Read More

Healthcare industry's global workforce mobility fast tracked with AI-powered recruitment platforms

Global healthcare talent is being mobilized with AI-powered recruitment platforms. As the healthcare industry faces rising demand and demographic pressure, these platforms are becoming essential tools...

Read More



Verastem Announces Positive RAMP 205 Results for Avutometinib Combo in Frontline Metastatic PDAC

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced positive updated safety and efficacy results from the RAMP 205...

Read More

Industry INSIDER

Veeda Lifesciences™

Bharat Biotech's oral cholera vaccine Hillchol demonstrates success in phase III clinical studies

Innovent Biologics announces the successful dosing of the first participant in its Phase 3 trial (HeriCare-Ovarian01) for IBI354 (HER2 ADC), targeting platinum-resistant ovarian cancer with HER2 expression...

Read More

NovelMed announce positive 12-week interim results from phase II trial of Ruxoprubart in adult patients with PNH

NovelMed, a clinical-stage biopharmaceutical company, announced positive 12-week interim results from the ongoing multi-dose phase II trial of Ruxoprubart, a novel complement-targeting immunotherapy...

Read More

WHO Foundation & Laerdal Global Health announce US$ 12.5 million to launch massive acute care scale up

A newly-announced philanthropic partnership between Laerdal Global Health and the WHO Foundation will fund WHO to scale up acute care training for health workers in select African countries...

Read More

Strides in Q4 delivers revenue at Rs. 1,190.4 crore, grew 17% YoY

Strides Pharma Science in its consolidated financial results for Q4FY25 delivered revenues to the tune of Rs. 1,190.4 crore registering a growth of 17% YoY. For the full year (FY25) ended March 31, 2025...

Read More

Ayush and herbal products exports grew 5.9 per cent in FY25

Exports of Ayush and herbal products from India during the fiscal year 2024-25 grew 5.86 per cent, with the quantity growing almost 21.46 per cent as compared to the previous fiscal year...

Read More

Employee SPOTLIGHT

Veeda™ Lifesciences

Introducing ElevateXchange: Veeda's New Employee-Connect Initiative

ElevateXchange fosters meaningful dialogue between Veeda leaders and new team members-driving alignment, inspiration, and collaborative growth from day one.

Read More!



Fostering Cross-Border Collaboration Through ElevateXchange

Veeda Lifesciences India and Europe teams came together for an ElevateXchange session with COO James Brook-building alignment, sharing insights, and strengthening global team synergy.

Regulatory AFFAIRS

Veeda™ Lifesciences

Veeda Contributes to Indian Council of Medical Research's Stakeholder Meet on Phase-1 Approvals

Veeda Lifesciences was invited to a high-level stakeholder meeting organized by the Indian Council of Medical Research (ICMR) and co-chaired by the Drug Controller General of India (DCGI) to discuss faster approvals for Phase-1 clinical trials. As a leader in early-phase research, Veeda provided key recommendations on streamlining regulatory processes for New Chemical Entities (NCEs), reinforcing its thought leadership in clinical development.

Leadership Presence at Pharmacovigilance Training by Central Drugs Standard Control Organisation

Veeda demonstrated its regulatory commitment through active participation in a regional pharmacovigilance training program hosted by the West Zone office of the Central Drugs Standard Control Organisation (CDSCO). Dr. Kiran Marthak joined as a panelist, offering deep insights on evolving compliance needs and real-world challenges, strengthening Veeda's role in advancing drug safety standards.

Successful Registration Under New CDSCO CRO Framework

In line with the Central Drugs Standard Control Organisation's (CDSCO) updated guidelines, Veeda has completed registration of all its operational sites-including Ahmedabad, Mehsana, and the Biopharma facility-under the new CRO framework via the SUGAM portal (e-governance regulatory portal). This timely compliance reflects Veeda's continued focus on operational transparency and regulatory alignment.

US FDA Approves Blood Test for Early Alzheimer's Detection

The US FDA has approved the first-ever blood test for early-stage detection of Alzheimer's disease, marking a major advancement in neurodiagnostic tools and offering hope for earlier intervention.

info@veedalifesciences.com

www.veedalifesciences.com

Contact Us

Address:

Corporate Office

VEEDA CLINICAL RESEARCH LIMITED
Satyamev House, Nr. Shalin Bunglow,
Prahladnagar, Ahmedabad 380015

Registered Office

Shivalik Plaza-A, Near IIM Ambawadi,
Ahmedabad- 380015, Gujarat, India. CIN
No. U73100GJ2004PTC044023

Global Offices

- India
- Greece
- Italy
- Ireland



info@veedalifesciences.com
www.veedalifesciences.com

Excellence In Everything